The Food and Drug Administration up to date the warning label on GLP-1 prescription drugs in September of 2023 to listing intestinal obstructions, a significant and perhaps daily life-threatening ailment often known as ileus, being a possible adverse impact. Zepbound is administered once weekly by subcutaneous (underneath the skin) injection. https://lukasisbio.bloginder.com/29227273/getting-my-zepbound-finder-to-work